EMA Authorised: Tasigna (nilotinib) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Tasigna (nilotinib) for chronic myeloid leukemia (BCR-ABL positive); the marketing authorisation holder is Novartis Eur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Novartis Europharm Limited. Decision date: 17/12/2025